Guardant Health, Inc. (NASDAQ:GH) Shares Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP lifted its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 96.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,315,600 shares of the company's stock after acquiring an additional 1,138,300 shares during the period. Two Sigma Advisers LP owned 1.87% of Guardant Health worth $70,742,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Guardant Health by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock valued at $368,205,000 after buying an additional 350,606 shares in the last quarter. Deep Track Capital LP boosted its stake in Guardant Health by 7.0% during the 4th quarter. Deep Track Capital LP now owns 6,419,566 shares of the company's stock valued at $196,118,000 after purchasing an additional 419,006 shares during the last quarter. Two Sigma Investments LP boosted its stake in Guardant Health by 38.5% during the 4th quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company's stock valued at $57,761,000 after purchasing an additional 525,368 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in Guardant Health by 19.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after purchasing an additional 238,037 shares during the last quarter. Finally, Nikko Asset Management Americas Inc. boosted its stake in Guardant Health by 15.6% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after purchasing an additional 197,729 shares during the last quarter. Institutional investors own 92.60% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on the company. JPMorgan Chase & Co. increased their target price on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Morgan Stanley raised their price target on Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Mizuho started coverage on Guardant Health in a research note on Thursday, April 10th. They issued an "outperform" rating and a $55.00 price target on the stock. Piper Sandler restated an "overweight" rating and issued a $60.00 price target (up from $50.00) on shares of Guardant Health in a research note on Tuesday, May 6th. Finally, The Goldman Sachs Group raised their price target on Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Twenty-one investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $52.32.

Guardant Health Stock Up 2.6%

GH traded up $0.95 on Friday, hitting $38.00. The company had a trading volume of 1,373,039 shares, compared to its average volume of 2,145,131. The company has a market cap of $4.71 billion, a PE ratio of -10.67 and a beta of 1.49. Guardant Health, Inc. has a 12-month low of $20.14 and a 12-month high of $52.92. The business's fifty day simple moving average is $43.39 and its 200 day simple moving average is $40.16.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business had revenue of $203.47 million during the quarter, compared to analyst estimates of $189.91 million. During the same quarter in the previous year, the business earned ($0.46) earnings per share. The company's revenue for the quarter was up 20.8% compared to the same quarter last year. On average, analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of the company's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the completion of the sale, the chief executive officer now owns 2,202,672 shares in the company, valued at $107,952,954.72. This represents a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 107,132 shares of company stock worth $5,248,393 over the last 90 days. Company insiders own 6.10% of the company's stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.